The use of supramolecular synthons as a strategy to control crystalline structure is a crucial factor in developing new solid forms with physicochemical properties optimized by design. However, to achieve this objective, it is necessary to understand the intermolecular interactions in the context of crystal packing. The feasibility of a given synthon depends on its flexibility to combine the drug with a variety...
The use of supramolecular synthons as a strategy to control the crystal structure is the key to the development of new solid forms with physicochemical properties optimized by design. However, to achieve this objective, it is necessary to understand intermolecular interactions in the context of crystalline packing. Identifying potential hydrogen bonding sites in the Active Pharmaceutical Ingredient (API) and se...